103 related articles for article (PubMed ID: 3415713)
1. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
Bichler J; Fichtl B; Siebeck M; Fritz H
Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
Bichler J; Siebeck M; Fichtl B; Fritz H
Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and anticoagulant effect of hirudin in man.
Markwardt F; Nowak G; Stürzebecher J; Griessbach U; Walsmann P; Vogel G
Thromb Haemost; 1984 Oct; 52(2):160-3. PubMed ID: 6523433
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
5. Studies on the pharmacokinetics of hirudin.
Markwardt F; Nowak G; Stürzebecher U; Walsmann P
Biomed Biochim Acta; 1987; 46(4):237-44. PubMed ID: 3632647
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic studies with recombinant hirudin in dogs.
Nowak G; Markwardt F; Fink E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
[TBL] [Abstract][Full Text] [Related]
9. Clinico-pharmacological studies with recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J; Vogel G
Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
[TBL] [Abstract][Full Text] [Related]
10. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of recombinant hirudin in healthy horses.
Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Boström SL; Hansson GF; Sarich TC; Wolzt M
Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of hirudin.
Vogel G; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):113-8. PubMed ID: 2459004
[TBL] [Abstract][Full Text] [Related]
14. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
15. The pharmacology of recombinant hirudin, a new anticoagulant.
Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological survey of recombinant hirudin.
Markwardt F; Fink G; Kaiser B; Klöcking HP; Nowak G; Richter M; Stürzebecher J
Pharmazie; 1988 Mar; 43(3):202-7. PubMed ID: 3380865
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration.
Cardot JM; Lefèvre GY; Godbillon JA
J Pharmacokinet Biopharm; 1994 Apr; 22(2):147-56. PubMed ID: 7815310
[TBL] [Abstract][Full Text] [Related]
20. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
Kouz J; Czech J; Nicolay U; Dickneite G
Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
